Author

Linh Tran

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract B053: RAS(ON) inhibition, but not chemotherapy, sensitizes RAS mutant PDAC to immunotherapy via tumor microenvironment remodeling in preclinical models

Pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to immune checkpoint blockade and combining anti-PD-(L)1 therapy with standard-of-care chemotherapy has not improved clinical outcomes over chemotherapy alone. Because oncogenic RAS drives both tumor growth and tumor-intrinsic immune suppression, we h...

L. Grigoryan, Keith Macaraig, Victor Batiste et al. · Cancer Research · 0 citations

Aug 2026

Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS-mutant Pancreatic and Lung Cancer

Combined treatment with the AXL inhibitor bemcentinib together with the RAS(ON) multi-selective tri-complex inhibitor RMC-7977 (RASi) or the ERK-selective inhibitor SCH772984 (ERKi) significantly enhanced growth suppression in human KRAS-mutant pancreatic and lung cancer models.

Yan-Pang Ching, Shruthi Narayanan, Jeffrey A. Klomp et al. · bioRxiv · 0 citations